Viewing Company Celgene Corp | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

Celgene Corp Stock Symbol: CELG-Q

Last Price Recorded: $127.5800 on 2017-08-17

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-08-09 COMMENT Cameron Hurst

This is big and is more diversified than others, so you are not buying a binary outcome stock. He likes biotech, but would approach it from the equal weight standpoint by going through the SPDR S&P Biotech ETF (XBI-N). Celgene is a good name.


Price:
$135.570
Subject:
US EQUITIES
Bias:
BEARISH on CANADIAN MARKET
Owned:
Unknown
2017-08-01 PAST TOP PICK Bruce Murray

(A Top Pick Oct 4/16. Up 28.79%.) Still loves this and has a target price of about $160 2-3 years out. It has some great products and has a whole plethora of new products before the FDA.


Price:
$135.180
Subject:
NORTH AMERICAN
Bias:
BULLISH on US MARKET
Owned:
Yes
2017-07-31 COMMENT Brooke Thackray

Biotech stocks do really well this time of year from June 23 until September 13. Since 2002 they have been positive 88% of the time, and outperformed the S&P 500 88% of the time. July tends to be the best month for biotech stocks. The chart shows higher lows and a little bit of a break out. From a technical standpoint, this is positive. Very often, he will sell his biotech stocks later on in August.


Price:
$135.410
Subject:
TECHNICAL ANALYSIS & SEASONAL INVESTING
Bias:
CAUTIOUS
Owned:
Unknown
2017-07-25 PAST TOP PICK John O'Connell, CFA

(A Top Pick July 6/16. Up 31.77%.) This is still a Buy. It has cancer drugs that work. Very, very profitable. Amazing balance sheet. Very, very strong management team.


Price:
$136.440
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-06-14 PAST TOP PICK John O'Connell, CFA

(A Top Pick July 6/16. Up 16%.) Biotechnology company involved in cancer drugs. 20% earnings growth. Trading at 14X earnings. Strong balance sheet. Still a buy.


Price:
$121.040
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-06-02 PARTIAL BUY Brian Acker, CA

He likes this. It closed at $116.41, and his model price is $145.80, a 25% upside. Maybe this gets down to $97, which would be an absolute Buy. Buy half a position now, and when it went cheaper, Buy the other half.


Price:
$118.730
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH on US$
Owned:
Yes
2017-05-29 TOP PICK Teal Linde

They are growing nicely.  One of the fastest growing large cap pharma in North America.  Their slowest growth year was 14%.  Otherwise they averaged 20% per year over the last 10 years.  (Analysts’ target: $147) .


Price:
$116.780
Subject:
NORTH AMERICAN - LARGE/MID CAPS
Bias:
SELECTIVE
Owned:
Yes
2017-05-26 PAST TOP PICK Stan Wong

(A Top Pick April 6/16. Up 8%.) Their cancer drug continues to do well. They have a strong pipeline behind that. The shares are trading at 15X forward earnings, with what he expects to be a 20% long-term growth rate. That gives a PEG ratio of .75. Still very cheap.


Price:
$116.780
Subject:
NORTH AMERICAN - LARGE & ETFs
Bias:
UNKNOWN
Owned:
Yes
2017-05-19 DON'T BUY John Petrides

Trading at 25X price to cash flow, a bit too rich for him. The stock is up 17% over the last 12 months. The bet on this company is that you have faith in their pipeline executing on future drugs. There is much more attractive value in healthcare outside of this.


Price:
$116.930
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
No
2017-05-10 PAST TOP PICK Paul Macdonald

(A Top Pick Feb 22/17. Up 14.45%.) One of the few companies that can double their revenue between now and 2020, without actually having pipeline success. Trading at 16X next year’s.


Price:
$119.680
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
Yes
2017-05-10 TOP PICK Paul Macdonald

They are able to double revenues between now and 2020 without a lot of pipeline success. The PEG ratio at .8, is not painful for a lot of their growth. Great financial metrics and you are not paying a lot for it. Some recent volatility presents a decent entry point. (Analysts’ price target is $146.)


Price:
$119.680
Subject:
HEALTHCARE
Bias:
UNKNOWN
Owned:
Yes
2017-04-19 TOP PICK Bruce Murray

One of the surest growth stocks out there. They have a product called Revlimid which treats a whole series of blood cancers. The one they have right now is multiple myeloma, and it prolongs people’s lives substantially. They are going to grow revenue 25% over the next 4 years. It is selling at 18X. Thinks it gets close to $200 in the next couple of years. (Analysts’ price target is $143.)


Price:
$122.920
Subject:
LARGE CAP GROWTH & DIVIDENDS
Bias:
UNKNOWN
Owned:
Yes
2017-03-07 BUY on WEAKNESS John Stephenson

He really likes this. If you look at all the biotechs, this has got the best pipeline of any. This is one you pick up on weakness. Earnings growth is very strong. Valuation is reasonable. Healthcare is probably a sector that shines in the 2nd half when we get through the Trump agenda.


Price:
$122.080
Subject:
NORTH AMERICAN - LARGE & RESOURCE
Bias:
BULLISH
Owned:
Yes
2017-02-22 TOP PICK Paul Macdonald

Just added this in January. The company has a blood cancer drug that is really going to be the dominant player in that space. Has a huge pipeline of trials that are coming out with Revlimid . Also, diversifying their pipeline with Otezla. Between now and 2020, they are going to double revenues, and they don’t need success in their pipeline to do so. Trading at 16.9X forward earnings, and that grows down to 14X 24 months out. (Analysts’ price target is $140.27.)


Price:
$119.270
Subject:
HEALTHCARE
Bias:
BULLISH on HEALTH CARE
Owned:
Yes
2017-02-09 DON'T BUY John Petrides

They are a biotech large cap with a drug that has been one of their cash cows (50% of sales) and they are using that to bolster their pipeline.  He really likes it.  However, there are more attractive stocks in the healthcare space.  There is better value to be had elsewhere in the space.


Price:
$116.740
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
Showing 1 to 15 of 45 entries
<< < 1 2 3 > >>

No Comments.


You must be logged in to comment.